Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 11/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.64 |
| ▸ | PLG | P00747 | 5/20 | 0.64 |
| ▸ | F2 | P00734 | 5/20 | 0.64 |
| ▸ | KLK1 | P06870 | 3/20 | 0.64 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.64 |
| ▸ | F12 | P00748 | 2/20 | 0.62 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | PLAT | P00750 | 2/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.50 |
| ▸ | C1S | P09871 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15601786 | 0.79 | LCK (0.62) | PLAUCYP2A6CYP1A2 | |
| SCHEMBL3370031 | 0.78 | PLAU (1.00) | PLAUPRSS1PLGF2KLK1 | |
| SCHEMBL29941688 | 0.78 | PLAU (1.00) | PLAUPRSS1PLGF2KLK1 | |
| SCHEMBL23640969 | 0.78 | CYP2A6 (0.52) | PLAUPRSS1PLGF2KLK1 | |
| SCHEMBL7336455 | 0.77 | PLAU (0.78) | PLAUPRSS1PLGF2KLK1 | |
| SCHEMBL3111985 | 0.77 | PLAU (0.59) | PLAUPRSS1PLGF2KLK1 | |
| 4-Methylbenzimidamide SCHEMBL524027 | 0.77 | LMNA (0.59) | PLAUPRSS1F2F12PRSS2 | |
| SCHEMBL3301671 | 0.77 | F12 (1.00) | PLAUPRSS1PLGF2KLK1 | |
| SCHEMBL31499215 | 0.77 | F12 (1.00) | PLAUPRSS1PLGF2KLK1 | |
| SCHEMBL7362642 | 0.77 | PLAU (0.72) | PLAUPRSS1PLGF2KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9808452-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170100390-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170100390-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | PLAU 1328/4885PRSS1 717/4885PLG 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.